0000950170-22-018183.txt : 20220907 0000950170-22-018183.hdr.sgml : 20220907 20220907163049 ACCESSION NUMBER: 0000950170-22-018183 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220906 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing FILED AS OF DATE: 20220907 DATE AS OF CHANGE: 20220907 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Allena Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001624658 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 452729920 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38268 FILM NUMBER: 221231505 BUSINESS ADDRESS: STREET 1: 142 -F NORTH ROAD, SUITE 150 CITY: SUDBURY STATE: MA ZIP: 01776 BUSINESS PHONE: 617-467-4577 MAIL ADDRESS: STREET 1: 142 -F NORTH ROAD, SUITE 150 CITY: SUDBURY STATE: MA ZIP: 01776 8-K 1 alna-20220906.htm 8-K 8-K
false00016246580001624658dei:FormerAddressMember2022-09-062022-09-0600016246582022-09-062022-09-06

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 06, 2022

 

 

Allena Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-38268

45-2729920

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

142-F North Road

Suite 150

 

Sudbury, Massachusetts

 

01776

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (617) 467-4577

 

 

One Newton Executive Park, Suite 202

Newton, Massachusetts 02462

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.001 per share

 

ALNA

 

The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously reported, on August 23, 2022, Allena Pharmaceuticals, Inc. (the "Company") received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that (i) the Company has not regained compliance with its requirement to maintain a minimum closing bid price of $1.00 per share for the required period (the “Minimum Bid Price Requirement”), and (ii) failure to regain compliance with the Minimum Bid Price Requirement serves as a basis for delisting the Company’s securities from The Nasdaq Capital Market unless the Company timely requests a hearing before a Nasdaq Hearings Panel (the "Panel").

On August 30, 2022, the Company requested a hearing before the Panel, which temporarily stayed the suspension of trading and delisting of the Company’s common stock.

On September 2, 2022, after considering all strategic alternatives, the Company filed a voluntary petition for relief under the provisions of Chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the District of Delaware. The bankruptcy case is being administered under the caption In re Allena Pharmaceuticals, Inc. (Case No. 22-10842).

In light of the Chapter 11 filing, the Company withdrew its request for a hearing. On September 6, 2022, the Company received notice from Nasdaq that its shares will be suspended at the open of business on September 8, 2022. Nasdaq is expected to file a Form 25 Notification of Delisting with the Securities Exchange Commission when all internal appeal periods have run.

Cautionary Information Regarding Trading in the Company’s Securities.

The Company’s securityholders are cautioned that trading in the Company’s securities during the pendency of the Chapter 11 cases is highly speculative and poses substantial risks. Trading prices for the Company’s securities may bear little or no relationship to the actual recovery, if any, by holders thereof in the Company’s Chapter 11 case. As noted above, the Company currently expects that the Chapter 11 filing will result in, among other things, the cancellation or extinguishment of all outstanding shares of the Company’s capital stock without any payment or other distribution on account of those shares. Accordingly, the Company urges extreme caution with respect to existing and future investments in its securities.

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements concerning the outcome of the Company's Chapter 11 filing and the listing of the Company's equity securities on the Nasdaq Stock Market. Any forward-looking statements in this Current Report on Form 8-K are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Additional risks and uncertainties include, but are not limited to: the Company’s Chapter 11 strategy; risks and uncertainties associated with Chapter 11 proceedings generally; the negative impacts on the Company’s businesses as a result of filing for and operating under Chapter 11 protection; the time, terms and ability to confirm a Chapter 11 plan of reorganization for the Company’s businesses; the adequacy of the capital resources of the Company’s businesses and the difficulty in forecasting the liquidity requirements of the operations of its businesses; the unpredictability of the Company’s financial results while in Chapter 11 proceedings; the Company’s ability to discharge claims in Chapter 11 proceedings; negotiations with the holders of the Company’s indebtedness and its trade creditors and other significant creditors; and risks associated with the Company's ability to identify and consummate financing and strategic alternatives that yield additional value for shareholders. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, as well as discussions of potential risks, uncertainties and other important factors in the Company's subsequent filings with the Securities and Exchange Commission. All information in this Current Report on Form 8-K is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

Allena Pharmaceuticals, Inc.

 

 

 

 

Date:

September 7, 2022

By:

/s/ Kevin Brennan

 

 

 

Kevin Brennan
Vice President, Finance

 

 EX-101.SCH 2 alna-20220906.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 3 alna-20220906_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 4 alna-20220906_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity Ex Transition Period Securities Act File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications Document Information [Table] Document Information [Line Items] Former Address [Member] Entity Addresses, Address Type [Axis] Address Type [Domain] EX-101.PRE 5 alna-20220906_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document And Entity Information
Sep. 06, 2022
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 06, 2022
Entity Registrant Name Allena Pharmaceuticals, Inc.
Entity Central Index Key 0001624658
Entity Emerging Growth Company true
Securities Act File Number 001-38268
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 45-2729920
Entity Address, Address Line One 142-F North Road
Entity Address, Address Line Two Suite 150
Entity Address, City or Town Sudbury
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01776
City Area Code (617)
Local Phone Number 467-4577
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period true
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol ALNA
Security Exchange Name NASDAQ
Former Address [Member]  
Document Information [Line Items]  
Entity Address, Address Line One One Newton Executive Park, Suite 202
Entity Address, City or Town Newton
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02462
XML 7 alna-20220906_htm.xml IDEA: XBRL DOCUMENT 0001624658 dei:FormerAddressMember 2022-09-06 2022-09-06 0001624658 2022-09-06 2022-09-06 false 0001624658 8-K 2022-09-06 Allena Pharmaceuticals, Inc. DE 001-38268 45-2729920 142-F North Road Suite 150 Sudbury MA 01776 (617) 467-4577 One Newton Executive Park, Suite 202 Newton MA 02462 false false false false Common Stock, par value $0.001 per share ALNA NASDAQ true true EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 2 24 1 false 1 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.allenapharma.com/20220906/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports alna-20220906.htm alna-20220906.xsd alna-20220906_def.xml alna-20220906_lab.xml alna-20220906_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "alna-20220906.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 2, "dts": { "definitionLink": { "local": [ "alna-20220906_def.xml" ] }, "inline": { "local": [ "alna-20220906.htm" ] }, "labelLink": { "local": [ "alna-20220906_lab.xml" ] }, "presentationLink": { "local": [ "alna-20220906_pre.xml" ] }, "schema": { "local": [ "alna-20220906.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 30, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 1, "nsprefix": "alna", "nsuri": "http://www.allenapharma.com/20220906", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "alna-20220906.htm", "contextRef": "C_2fbeca38-4821-468b-aae7-436b22dd5bb0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "role": "http://www.allenapharma.com/20220906/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "alna-20220906.htm", "contextRef": "C_2fbeca38-4821-468b-aae7-436b22dd5bb0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 1, "tag": { "dei_AddressTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.", "label": "Address Type [Domain]" } } }, "localname": "AddressTypeDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220906/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220906/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220906/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220906/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220906/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220906/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220906/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220906/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220906/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220906/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220906/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220906/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityAddressesAddressTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Addresses, Address Type [Axis]" } } }, "localname": "EntityAddressesAddressTypeAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220906/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220906/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220906/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220906/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220906/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220906/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220906/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220906/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_FormerAddressMember": { "auth_ref": [ "r6", "r7" ], "lang": { "en-us": { "role": { "documentation": "Former address for entity", "label": "Former Address [Member]" } } }, "localname": "FormerAddressMember", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220906/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220906/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220906/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220906/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220906/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220906/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220906/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220906/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220906/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Form 10-Q", "Number": "249", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r7": { "Name": "Form 8-K", "Number": "249", "Publisher": "SEC", "Section": "308" }, "r8": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r9": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 14 0000950170-22-018183-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-22-018183-xbrl.zip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end